Latest Insider Transactions at Jazz Pharmaceuticals PLC (JAZZ)
This section provides a real-time view of insider transactions for Jazz Pharmaceuticals PLC (JAZZ). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Jazz Pharmaceuticals plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Jazz Pharmaceuticals plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 06
2024
|
Mary Elizabeth Henderson SVP, Technical Operations |
SELL
Open market or private sale
|
Direct |
1,410
-8.85%
|
$152,280
$108.3 P/Share
|
|
Aug 06
2024
|
Heather Ann Mc Sharry Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,608
-7.84%
|
$178,488
$111.35 P/Share
|
|
Aug 06
2024
|
Kenneth W O'Keefe Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,484
-5.22%
|
$164,724
$111.35 P/Share
|
|
Aug 06
2024
|
Anne O Riordan Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,484
-9.11%
|
$164,724
$111.35 P/Share
|
|
Aug 06
2024
|
Norbert G Riedel Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,484
-21.8%
|
$164,724
$111.35 P/Share
|
|
Aug 06
2024
|
Mark Douglas Smith Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,484
-13.98%
|
$164,724
$111.35 P/Share
|
|
Aug 06
2024
|
Rick E Winningham Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,484
-10.47%
|
$164,724
$111.35 P/Share
|
|
Aug 06
2024
|
Jennifer E. Cook Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,484
-13.98%
|
$164,724
$111.35 P/Share
|
|
Aug 02
2024
|
Patrick G Enright Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,731
+13.13%
|
-
|
|
Aug 02
2024
|
Heather Ann Mc Sharry Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,731
+15.39%
|
-
|
|
Aug 02
2024
|
Kenneth W O'Keefe Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,731
+11.59%
|
-
|
|
Aug 02
2024
|
Anne O Riordan Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,731
+18.64%
|
-
|
|
Aug 02
2024
|
Norbert G Riedel Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,731
+35.41%
|
-
|
|
Aug 02
2024
|
Mark Douglas Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,731
+26.0%
|
-
|
|
Aug 02
2024
|
Rick E Winningham Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,731
+20.84%
|
-
|
|
Aug 02
2024
|
Jennifer E. Cook Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,731
+26.0%
|
-
|
|
Aug 02
2024
|
Patrick Kennedy Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,731
+41.99%
|
-
|
|
Aug 02
2024
|
Seamus Mulligan Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,731
+0.32%
|
-
|
|
Aug 02
2024
|
Samantha Pearce EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,996
+22.51%
|
-
|
|
Aug 02
2024
|
Laura Hamill Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,731
+41.63%
|
-
|
|
Jun 07
2024
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
163
-2.41%
|
$17,604
$108.83 P/Share
|
|
May 03
2024
|
Neena M Patil EVP & Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,000
-12.01%
|
$545,000
$109.65 P/Share
|
|
Apr 05
2024
|
Renee D Gala President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,736
-3.04%
|
$199,640
$115.21 P/Share
|
|
Mar 07
2024
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,768
-21.14%
|
$205,088
$116.98 P/Share
|
|
Mar 06
2024
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,936
-9.86%
|
$230,384
$119.18 P/Share
|
|
Mar 05
2024
|
Renee D Gala President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,622
-5.97%
|
$423,774
$117.53 P/Share
|
|
Mar 05
2024
|
Bruce C Cozadd Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
22,436
-4.96%
|
$2,625,012
$117.53 P/Share
|
|
Mar 05
2024
|
Robert Iannone EVP, Global Head of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
4,294
-6.46%
|
$502,398
$117.53 P/Share
|
|
Mar 05
2024
|
Neena M Patil EVP & Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,432
-7.62%
|
$401,544
$117.53 P/Share
|
|
Mar 05
2024
|
Samantha Pearce EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,474
-12.76%
|
$289,458
$117.53 P/Share
|
|
Mar 01
2024
|
Patricia Carr SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,987
+22.48%
|
-
|
|
Mar 01
2024
|
Mary Elizabeth Henderson SVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
5,178
+24.52%
|
-
|
|
Mar 01
2024
|
Neena M Patil EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,348
+21.51%
|
-
|
|
Mar 01
2024
|
Samantha Pearce EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,065
+20.71%
|
-
|
|
Mar 01
2024
|
Robert Iannone EVP, Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
16,928
+20.29%
|
-
|
|
Mar 01
2024
|
Renee D Gala President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
19,916
+24.7%
|
-
|
|
Mar 01
2024
|
Patrick Kennedy Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,423
+50.0%
|
-
|
|
Mar 01
2024
|
Bruce C Cozadd Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
50,187
+9.99%
|
-
|
|
Mar 01
2024
|
Philip L Johnson EVP & Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+30.05%
|
$1,428,000
$119.65 P/Share
|
|
Mar 01
2024
|
Philip L Johnson EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,932
+50.0%
|
-
|
|
Jan 17
2024
|
Samantha Pearce EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,038
-6.75%
|
$123,522
$119.13 P/Share
|
|
Jan 17
2024
|
Samantha Pearce EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,210
+12.57%
|
-
|
|
Jan 17
2024
|
Robert Iannone EVP, Global Head of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
1,730
-3.37%
|
$205,870
$119.13 P/Share
|
|
Jan 17
2024
|
Robert Iannone EVP, Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
5,970
+10.42%
|
-
|
|
Jan 17
2024
|
Neena M Patil EVP & Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,656
-4.82%
|
$197,064
$119.13 P/Share
|
|
Jan 17
2024
|
Neena M Patil EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,087
+12.89%
|
-
|
|
Jan 17
2024
|
Patricia Carr SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,327
+15.27%
|
-
|
|
Jan 17
2024
|
Bruce C Cozadd Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,245
-2.96%
|
$1,457,155
$119.13 P/Share
|
|
Jan 17
2024
|
Bruce C Cozadd Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
26,545
+6.02%
|
-
|
|
Jan 17
2024
|
Renee D Gala President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,204
-7.28%
|
$381,276
$119.13 P/Share
|